New draft 2025 Clinical Practice Guidelines for the Early Detection of Prostate Cancer have been released for public comment, following two years of exhaustive work led by PCFA in close collaboration with experts and consumers from around Australia.
Prostate cancer is the most commonly diagnosed cancer in Australia, accounting for 16% of all cancers diagnosed and for 1 in 3 cancers diagnosed among Australian men.
The new Guidelines are designed to supersede the 2016 Clinical Practice Guidelines for PSA Testing, recognising that significant advancements in diagnosis and treatment have created an evidence-based pathway for a more structured testing program.
Notably, Australia will become the first country in the world to publish formal clinical guidelines on the early detection of prostate cancer, significantly strengthening our work towards zero deaths in our lifetime.
Join Host Katie Clift and a Panel of Experts – Professor Jeff Dunn AO, PCFA Chief of Mission and Head of Research, Associate Professor David Smith, Interim Deputy Director and Prostate Cancer Stream Lead at the Daffodil Centre and Adjunct Professor Peter Heathcote, one of Australia’s leading urologic surgeons for prostate cancer. Together, the panel will discuss the development of the draft Guidelines in detail.
The public consultation period for commenting on the 2025 draft Guidelines will close at midnight on May 25th 2025. Submissions can be made online or via email to research@pcfa.org.au.
For more information and support, please call 1800 22 00 99 or go to prostate.org.au.
HOST
Katie Clift
Director of International Public Relations Agency maybe, Global Moderator, Speaker & Breast Cancer Survivor
Katie Clift is Director of maybe, an international counter-cultural public relations agency. An MBA scholar of Warwick Business School. Katie has worked internationally on both sides of communications – in the media (radio, television & digital journalism) and as a PR, spokesperson, and corporate affairs executive - for both the private and public sectors. She has a decade of experience as a moderator, presenting sessions, interviews and press conferences globally, from the World Economic Forum in Davos to the Union for International Cancer Control’s World Cancer Congress and various in-person and online events. Katie was diagnosed with aggressive breast cancer in her 30s, and after 18 months of active treatment, returned to life and work more determined than ever to advocate for people affected by all types of cancer, and upscale communications for nonprofits globally.
PANELLISTS
Professor Jeff Dunn AO
Jeff is the Head of Research & Chief of Mission, Prostate Cancer Foundation of Australia; Professor of Social and Behavioural Science; and Chair of Cancer Survivorship, University of Southern Queensland; Immediate Past President, Union for International Cancer Control. In 2024 Professor Dunn was ranked by Stanford University as among the top 2% of scientists worldwide for oncology and clinical medicine confirming his status as an international leader in the social and behavioural aspects of cancer. Over the course of his 30-year career, Professor Dunn has pioneered patient-centred care, working across disciplines to build community capacity in cancer control, influencing local, national and global health policies and programs. His research has been published in more than 200 publications and Scival (2024) includes Prof Dunn as top three global high impact researchers in prostate cancer survivorship and quality of life. In 2014 Professor Dunn was appointed an Officer in the Order of Australia for distinguished service to medical administration through leadership of cancer control organisations and promotion of innovative and integrated cancer care programs.
A/Prof David Smith
Associate Professor David Smith is an epidemiologist and health service researcher. He leads the Prostate Cancer stream of research and is the Interim Deputy Director of the Daffodil Centre. He and his team have published and presented extensively in cancer epidemiology and outcomes research. He has experience in research across a number of urological cancers but his major interest is in prostate cancer. He has worked in the areas of risk factors and epidemiology of the disease, the effect of PSA testing on the population trends and in the patterns and quality of life outcomes of care for prostate cancer. He has multiple active collaborations with peak groups working in prostate cancer, including Prostate Cancer Foundation of Australia and Movember. He is dedicated to improving the lives of men living with prostate cancer and ensuring that supportive care and equity of access to the best outcomes are obtainable for all men.
Adjunct Professor Peter Heathcote
Peter is a urologic surgeon with a special interest in cancer of the prostate, robotic surgery and pelvic oncology with over 30 years of practice experience. He is Senior Urologist at the Princess Alexandra Hospital in Brisbane Australia and also holds appointments as an Adjunct Professor at the Australian Prostate Cancer Research Centre in Queensland, as a Senior Examiner in Urology at the Royal Australasian College of Surgeons, and as a Senior Lecturer in Medicine University of Queensland. He is a Past-President Urological Society of Australia and New Zealand and has been a performance assessor for the AHPRA Medical Board of Australia performance assessor since 2016. He has been involved in the work of Prostate Cancer Foundation of Australia over many years, lending his expertise and time in a voluntary capacity in pursuit of the mission. He is currently the Chair of the Expert Advisory Panel that has developed the draft 2025 Clinical Practice Guidelines for the Early Detection of Prostate Cancer.
